Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction, or GEJ, adenocarcinoma who have received a prior trastuzumab-based regimen.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca put volume heavy and directionally bearish
- FDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination Treatment
- AstraZeneca announces availability of Alexion rare disease therapy in China
- AstraZeneca’s Imfinzi and Imjudo approved in U.S. for NSCLC patients
- FDA approves tremelimumab combo for metastatic non-small cell lung cancer